Stay updated with breaking news from Meera Mohan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Faculty from an OncLive® Institutional Perspectives in Cancer webinar on multiple myeloma summarize the main messages from their presentations.
Meera Mohan, MD, MS, FACP, discusses the significance of CAR T-cell therapies and bispecific antibodies in patients with relapsed/refractory multiple myeloma.
Meera Mohan, MD, MS, FACP, discusses adverse effects associated with CAR T-cell therapy in relapsed/refractory multiple myeloma.
Meera Mohan, MD, MS, FACP, discusses the toxicities associated with T-cell–directed therapies in relapsed/refractory multiple myeloma.
Undergoing HSCT within 4 weeks of SARS-CoV-2 infection is associated with an increased risk of death at 90 days after HSCT, real-world data suggest.